GLP-1 receptor agonism in Alzheimer's disease after EVOKE: From single hypothesis to stratified program.

Authors

Anderson Matheus Pereira Da Silva, Diogo Haddad Santos

Published in

Journal of Alzheimer's disease : JAD. Pages 13872877261485580. Sep 10, 2026. Epub Sep 10, 2026.

Abstract

The phase 3 EVOKE and EVOKE + trials of oral semaglutide in early Alzheimer's disease missed their primary endpoint and every cognitive or functional secondary endpoint. A recent article by Hölscher revisits extension-phase data and reports partial separation at later timepoints, attributing the failure to limited brain penetration. We argue that attrited extension cohorts bear limited inferential weight and that the biomarker substudy, read in full, complicates a clean disease-modification reading. EVOKE does not refute the cardiometabolic hypothesis but reframes the open questions: which pathways, which patients, and which disease stages are most likely to benefit.

PMID:
42720565
Bibliographic data and abstract were imported from PubMed on 10 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.